CCO Management Series
The Importance of Pharmacokinetic Factors in Successful Antiretroviral Therapy
The Importance of Pharmacokinetic and Pharmacodynamic Factors in Successful Antiretroviral Therapy—2005 in Review
|
Module 1 of 4
|
CME Program Director:
John P. Phair, MD
- Courtney V. Fletcher, PharmD
|
|
|
 Courtney V. Fletcher, PharmD, provides an update on pharmacologic and pharmacokinetic data presented in the latter half of 2005. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the choice of appropriate population for pharmacologic clinical trials.
- List factors that affect the plasma level of drugs.
- Explain the importance of the inhibitory quotient in the choice of antiretroviral agent.
|
Pharmacokinetic And Pharmacodynamic Principles: A Guide For HIV Healthcare Professionals
|
Module 2 of 4
|
Program Director:
John P. Phair, MD
- Courtney V. Fletcher, PharmD
|
|
|
Topics covered include:
- Introduction
- Key Pharmacokinetic Concepts
- Steady State Concepts
- Pharmacodynamics
- Exposure-Response Relationships for Antiretrovirals
Learning Objectives
Upon completion of this activity, participants should be able to:
Review the relationship between drug concentration and effect, with reference to specific antiretroviral agents Discuss the characteristics of drug concentrations at steady state, and the impact of different dosing regimens Define key pharmacokinetic and pharmacodynamic parameters
|
Factors Associated With Pharmacokinetic Variability In HIV-Infected Patients
|
Module 3 of 4
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Why Is Interpatient Variability Important?
- What Factors Contribute to PK Variability?
- Drug-Drug Interactions
- Enzyme Inhibition and Induction
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss factors that can contribute to pharmacokinetic variability in HIV-infected patients Review pharmacokinetic variations associated with specific clinical settings, including patient demographics, hepatitis and renal disease, pregnancy, and pediatrics Explain why interpatient variability in drug concentrations is a clinically important issue
|
Integrating Pharmacokinetics Into Treatment Decisions: Strategies For Optimal Patient Care
|
Module 4 of 4
|
Program Director:
John P. Phair, MD
|
|
Topics covered include:
- Introduction
- Pharmacologic Data: From the PK Profile to the Patient Profile
- PK Parameters: What Drives Clinical Outcome?
- Achieving the Desired Drug Exposure
- Pharmacologic Metrics and Diagnostic Tests
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe pharmacokinetic parameters that may predict clinical outcomes Discuss recently observed drug-drug interactions between antiretroviral agents List advantages and disadvantages of various boosted protease inhibitor (PI) regimens
|
Interactive Case Challenges
Treatment of Tuberculosis in a Patient Coinfected With HIV
Program Director:
John P. Phair, MD
|
|
 Explore options for the optimal antiretroviral management of an HIV-infected patient with tuberculosis, including consideration of drug-drug interactions and drug availability in his country of origin. Learning Objectives
Upon completion of this activity, participants should be able to:
List potential adverse drug interactions that may occur between rifamycin antibiotics and antiretroviral drugs. Discuss the advantages and disadvantages of rifabutin vs rifampin treatment in HIV-infected patients. Outline current recommendations for treating tuberculosis in HIV-infected patients.
|
Management of an HIV-Infected Patient With Treatment-Associated Renal Abnormalities
Program Director:
John P. Phair, MD
|
|
Test your ability to select and modify antiretroviral regimens in a patient with renal abnormalities, and receive instant feedback on your choices. Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss management considerations for patients with renal abnormalities Describe common toxicities associated with specific antiretroviral agents List potential drug interactions between tenofovir and other antiretroviral agents
|
Management of Antiretroviral Adverse Effects in a Young HIV-Infected Woman
Program Director:
John P. Phair, MD
- Courtney V. Fletcher, PharmD
|
|
|
Evaluate the most appropriate strategies for preventing and managing antiretroviral adverse effects, and compare your choices with those of other readers. Learning Objectives
Upon completion of this activity, participants should be able to:
List antiretroviral combinations that require dose adjustments due to drug-drug interactions. Describe the symptoms and recommended treatment approaches for NRTI-induced lactic acidosis. Outline sex-specific treatment considerations, including considerations relative to patient weight.
|
CCO Expert Recaps
The Importance of Pharmacokinetic Factors in Successful Antiretroviral Therapy
Program Director:
John P. Phair, MD
- Courtney V. Fletcher, PharmD
|
|
|
 Learning Objectives
Upon completion of this activity, participants should be able to:
Outline key pharmacologic concepts that are relevant to antiretroviral therapy. Review the role of pharmacokinetics in the development of optimal treatment strategies for HIV-infected patients. Discuss factors that can influence pharmacokinetics in HIV-infected patients.
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.
Pharmacist and nursing credit provided through the cosponsorship of Medical Education Collaborative and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|